Cargando…

Association between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium: a single-center retrospective study

BACKGROUND: Vancomycin is commonly used to treat Enterococcus faecium (E. faecium) bacteremia. However, there are very few studies on the association between the trough concentration, area under the curve from 0 to 24 h /minimum inhibitory concentration (AUC(24)/MIC) ratio, and the therapeutic effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakakura, Ichiro, Sakakura, Kota, Imanishi, Kaori, Sako, Rumi, Yamazaki, Kunio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485087/
https://www.ncbi.nlm.nih.gov/pubmed/31093330
http://dx.doi.org/10.1186/s40780-019-0138-2
_version_ 1783414211260448768
author Nakakura, Ichiro
Sakakura, Kota
Imanishi, Kaori
Sako, Rumi
Yamazaki, Kunio
author_facet Nakakura, Ichiro
Sakakura, Kota
Imanishi, Kaori
Sako, Rumi
Yamazaki, Kunio
author_sort Nakakura, Ichiro
collection PubMed
description BACKGROUND: Vancomycin is commonly used to treat Enterococcus faecium (E. faecium) bacteremia. However, there are very few studies on the association between the trough concentration, area under the curve from 0 to 24 h /minimum inhibitory concentration (AUC(24)/MIC) ratio, and the therapeutic effect of vancomycin on E. faecium bacteremia. This study aimed to investigate the associations between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with E. faecium bacteremia. METHODS: This retrospective study included patients with E. faecium bacteremia who received vancomycin between April 2012 and February 2018 at a single acute care hospital in Japan. Patients who received renal replacement therapy (hemodialysis or continuous hemodiafiltration), had an unmeasured serum vancomycin concentration, with unmeasured laboratory values, or received other antibiotics for treating E. faecium bacteremia were excluded from the study. The bivariate associations between 30-day all-cause mortality and patient characteristics were assessed. RESULTS: Among 87 patients diagnosed with E. faecium bacteremia, 45 were included in the final analysis. Of these, 12 (26.7%) died within 30 days of the diagnosis. The vancomycin trough concentration was higher in the 30-day all-cause mortality patients than in the survival patients (20.5 vs. 14.6 μg/mL; P = 0.022). There was no significant difference in the proportion of patients with a vancomycin AUC(24)/MIC ≤389 between the groups. The 30-day all-cause mortality patients showed a higher Charlson Comorbidity Index (CCI) and Sequential Organ Failure Assessment score at the first measurement of the vancomycin trough concentration than the survival patients. The same finding was observed among patients with a high CCI score (≥5 points). CONCLUSIONS: Whereas the vancomycin trough concentration and AUC(24)/MIC ratio were not associated with mortality in patients with E. faecium bacteremia, disease severity was associated with mortality in these patients.
format Online
Article
Text
id pubmed-6485087
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64850872019-05-16 Association between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium: a single-center retrospective study Nakakura, Ichiro Sakakura, Kota Imanishi, Kaori Sako, Rumi Yamazaki, Kunio J Pharm Health Care Sci Research Article BACKGROUND: Vancomycin is commonly used to treat Enterococcus faecium (E. faecium) bacteremia. However, there are very few studies on the association between the trough concentration, area under the curve from 0 to 24 h /minimum inhibitory concentration (AUC(24)/MIC) ratio, and the therapeutic effect of vancomycin on E. faecium bacteremia. This study aimed to investigate the associations between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with E. faecium bacteremia. METHODS: This retrospective study included patients with E. faecium bacteremia who received vancomycin between April 2012 and February 2018 at a single acute care hospital in Japan. Patients who received renal replacement therapy (hemodialysis or continuous hemodiafiltration), had an unmeasured serum vancomycin concentration, with unmeasured laboratory values, or received other antibiotics for treating E. faecium bacteremia were excluded from the study. The bivariate associations between 30-day all-cause mortality and patient characteristics were assessed. RESULTS: Among 87 patients diagnosed with E. faecium bacteremia, 45 were included in the final analysis. Of these, 12 (26.7%) died within 30 days of the diagnosis. The vancomycin trough concentration was higher in the 30-day all-cause mortality patients than in the survival patients (20.5 vs. 14.6 μg/mL; P = 0.022). There was no significant difference in the proportion of patients with a vancomycin AUC(24)/MIC ≤389 between the groups. The 30-day all-cause mortality patients showed a higher Charlson Comorbidity Index (CCI) and Sequential Organ Failure Assessment score at the first measurement of the vancomycin trough concentration than the survival patients. The same finding was observed among patients with a high CCI score (≥5 points). CONCLUSIONS: Whereas the vancomycin trough concentration and AUC(24)/MIC ratio were not associated with mortality in patients with E. faecium bacteremia, disease severity was associated with mortality in these patients. BioMed Central 2019-05-16 /pmc/articles/PMC6485087/ /pubmed/31093330 http://dx.doi.org/10.1186/s40780-019-0138-2 Text en © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Nakakura, Ichiro
Sakakura, Kota
Imanishi, Kaori
Sako, Rumi
Yamazaki, Kunio
Association between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium: a single-center retrospective study
title Association between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium: a single-center retrospective study
title_full Association between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium: a single-center retrospective study
title_fullStr Association between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium: a single-center retrospective study
title_full_unstemmed Association between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium: a single-center retrospective study
title_short Association between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium: a single-center retrospective study
title_sort association between vancomycin pharmacokinetic/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible enterococcus faecium: a single-center retrospective study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6485087/
https://www.ncbi.nlm.nih.gov/pubmed/31093330
http://dx.doi.org/10.1186/s40780-019-0138-2
work_keys_str_mv AT nakakuraichiro associationbetweenvancomycinpharmacokineticpharmacodynamicparameterspatientcharacteristicsandmortalityinpatientswithbacteremiacausedbyvancomycinsusceptibleenterococcusfaeciumasinglecenterretrospectivestudy
AT sakakurakota associationbetweenvancomycinpharmacokineticpharmacodynamicparameterspatientcharacteristicsandmortalityinpatientswithbacteremiacausedbyvancomycinsusceptibleenterococcusfaeciumasinglecenterretrospectivestudy
AT imanishikaori associationbetweenvancomycinpharmacokineticpharmacodynamicparameterspatientcharacteristicsandmortalityinpatientswithbacteremiacausedbyvancomycinsusceptibleenterococcusfaeciumasinglecenterretrospectivestudy
AT sakorumi associationbetweenvancomycinpharmacokineticpharmacodynamicparameterspatientcharacteristicsandmortalityinpatientswithbacteremiacausedbyvancomycinsusceptibleenterococcusfaeciumasinglecenterretrospectivestudy
AT yamazakikunio associationbetweenvancomycinpharmacokineticpharmacodynamicparameterspatientcharacteristicsandmortalityinpatientswithbacteremiacausedbyvancomycinsusceptibleenterococcusfaeciumasinglecenterretrospectivestudy